Brief: Lee's Pharmaceutical Holdings Says Idmc Recommends Discontinuation Of Trial For Liver Cancer Treatment
05/08/2019 02:25
Aug 5 (Reuters) - Lee's Pharmaceutical Holdings Ltd
0950.HK :
* IDMC RECOMMENDED DISCONTINUATION OF PHASE 3 CLINICAL TRIAL
FOR
ONCOLYTIC IMMUNOTHERAPY FOR ADVANCED LIVER CANCER
* INTERIM RESULTS OF TREATMENT SUGGEST THAT THE STUDY IS
UNLIKELY
TO MEET PRIMARY OBJECTIVE
Source text for Eikon: urn:newsml:reuters.com:*:nHKS7TZBHf
Further company coverage: 0950.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Lee's Pharmaceutical Holdings
See all newsHong Kong's Lee's Pharmaceutical H1 profit jumps on higher-margin product sales
Brief: Lee's Pharmaceutical Expects H1 Net Profit Of HK$85 Million-HK$95 Million
Brief: Lee's Pharmaceutical Says Investigational New Drug Application For ADC Project ZK2401 Accepted By NMPA
Brief: Ashlins Pharmaceuticals And Lee's Pharm Announce Exclusive License And Supply Agreement Valued At Up To $31 Million
Brief: Lee's Pharmaceutical Says Entered Licensing Agreement With Ashlins Ocular Pharmaceuticals